Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network

被引:0
|
作者
Conover, Mitchell M. [1 ,2 ]
Albogami, Yasser [1 ,3 ]
Hardin, Jill [1 ,2 ]
Reich, Christian G. [1 ,4 ]
Ostropolets, Anna [1 ,2 ,5 ]
Ryan, Patrick B. [1 ,2 ,5 ]
Observational Hlth Data Sci and Informatics OHDSI Res Network
机构
[1] Observat Hlth Data Sci & Informat, New York, NY 10032 USA
[2] Johnson & Johnson, Observat Hlth Data Analyt, Titusville, NJ 08560 USA
[3] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh, Saudi Arabia
[4] IQVIA, Real World Solut, Cambridge, MA USA
[5] Columbia Univ, Dept Biomed Informat, New York, NY USA
关键词
chronic lower respiratory disease; common data model; glucagon-like peptide 1 receptor agonists; pharmacoepidemiology; real world data; real world evidence; reliability; replicability; reproducibility; transparency; REPRODUCIBILITY; CALIBRATION; BALANCE;
D O I
10.1002/pds.70087
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
IntroductionThe aim of this study is to use observational methods to evaluate reliability of evidence generated by a study of the effect of glucagon-like peptide 1 receptor agonists (GLP-1RA) on chronic lower respiratory disease (CLRD) outcomes among Type-2 diabetes mellitus (T2DM) patients.Research Design and MethodsWe independently reproduced a study comparing effects of GLP-1RA versus dipeptidyl peptidase-4 inhibitors (DPP4-i) on CLRD outcomes among patients with T2DM and prior CLRD. We reproduced inputs and outputs using the original study data (national administrative claims) and evaluated the robustness of results in comparison to alternate design/analysis decisions. To evaluate generalizability, we applied an analysis protocol and conducted a meta-analysis across a research network that includes a diverse array of populations and data sources. We also produced additional analyses evaluating individual drugs within the GLP-1RA class and CLRD outcomes.ResultsWe confirmed alignment of study inputs and outputs and closely reproduced effect estimates and sensitivity analyses. Adjusted effect estimates were robust to empirical calibration. Network meta-analysis confirmed original findings but indicated weaker effects than originally published. Meta-analysis of drugs within the GLP-1RA class against DPP4-i provided evidence that effects vary within the GLP-1RA class, indicating stronger effects for exenatide and weaker effects of dulaglutide.ConclusionsThis study supports and establishes the reliability of the original study by (1) producing consistent findings in a range of alternate databases and populations, (2) demonstrating effects for multiple drugs within the GLP-1RA class, and (3) independently confirming the reproducibility of the original study and its findings. This reliability evaluation provides the beginnings of a broader framework for using standardized tools and distributed data networks to systematically interrogate the reliability of findings generated using observational data.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities
    Lund, Asger
    Knop, Filip K.
    Vilsboll, Tina
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (05) : 407 - 414
  • [42] Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective
    Fisher, M.
    DIABETES OBESITY & METABOLISM, 2015, 17 (04): : 335 - 342
  • [43] Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
    Lovshin, Julie A.
    CANADIAN JOURNAL OF DIABETES, 2017, 41 (05) : 524 - 535
  • [44] The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
    Yin, Win L.
    Bain, Steve C.
    Min, Thinzar
    DIABETES THERAPY, 2020, 11 (04) : 835 - 844
  • [45] Cancer incidence in Japanese patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists
    Ishibashi, R.
    Koshizaka, M.
    Ishikawa, T.
    Sato, J.
    Yoshimoto, H.
    Kitsuregawa, M.
    Goda, K.
    Yokote, K.
    Mitsutake, N.
    DIABETOLOGIA, 2024, 67 : S490 - S490
  • [46] Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes
    Frias, Juan Pablo
    JOURNAL OF FAMILY PRACTICE, 2018, 67 (06): : S25 - S34
  • [47] Advantages of glucagon-like peptide-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus: A review
    Demidova, Tatiana Yu.
    Titova, Victoria V.
    Izmaylova, Maryam Ya.
    TERAPEVTICHESKII ARKHIV, 2023, 95 (10) : 876 - 880
  • [48] Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes
    Guo, Xueyuan
    Sang, Caihua
    Tang, Ribo
    Jiang, Chenxi
    Li, Songnan
    Liu, Nian
    Long, Deyong
    Du, Xin
    Dong, Jianzeng
    Ma, Changsheng
    DIABETES OBESITY & METABOLISM, 2023, 25 : 53 - 63
  • [49] Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes
    Patel, Dhiren
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 : S29 - S42
  • [50] Comparative Effects of Glucagon-like Peptide 1 Receptor Agonists and Metformin on Glaucoma Risk in Patients with Type 2 Diabetes
    Muayad, Jawad
    Loya, Asad
    Hussain, Zain S.
    Chauhan, Muhammad Z.
    Alsoudi, Amer F.
    De Francesco, Ticiana
    Ahmed, Iqbal Ike K.
    OPHTHALMOLOGY, 2025, 132 (03)